journal
Journals Tumour Biology : the Journal o...

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine

https://read.qxmd.com/read/37545291/lack-of-clinical-utility-of-serum-macrophage-migration-inhibitory-factor-mif-for-monitoring-therapy-response-and-estimating-prognosis-in-advanced-lung-cancer
#1
JOURNAL ARTICLE
Alexander Rupp, Sophie Bahlmann, Nicolai Trimpop, Joachim von Pawel, Stefan Holdenrieder
BACKGROUND: Lung cancer is a major burden to global health and is still among the most frequent and most lethal malignant diseases. Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine involved in a variety of processes including tumorigenesis, formation of a tumor microenvironment and metastasis. It is therefore a potential prognostic biomarker in malignant diseases. OBJECTIVE: In this study, we investigated the applicability of MIF in serum samples as a biomarker in lung cancer...
August 2, 2023: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://read.qxmd.com/read/37545290/combined-use-of-cyfra-21-1-and-ca-125-predicts-survival-of-patients-with-metastatic-nsclc-and-stable-disease-in-impower150
#2
JOURNAL ARTICLE
Anika Mang, Wei Zou, Vinzent Rolny, Martin Reck, Daniel Cigoianu, Katja Schulze, Stefan Holdenrieder, Mark A Socinski, David S Shames, Birgit Wehnl, Namrata S Patil
BACKGROUND: Patients with non-small cell lung cancer (NSCLC) and stable disease (SD) have an unmet clinical need to help guide early treatment adjustments. OBJECTIVE: To evaluate the potential of tumor biomarkers to inform on survival outcomes in NSCLC SD patients. METHODS: This post hoc analysis included 480 patients from the IMpower150 study with metastatic NSCLC, treated with chemotherapy, atezolizumab and bevacizumab combinations, who had SD at first CT scan (post-treatment initiation)...
August 2, 2023: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://read.qxmd.com/read/37545289/comparing-modeling-strategies-combining-changes-in-multiple-serum-tumor-biomarkers-for-early-prediction-of-immunotherapy-non-response-in-non-small-cell-lung-cancer
#3
JOURNAL ARTICLE
Frederik A van Delft, Milou M F Schuurbiers, Mirte Muller, Sjaak A Burgers, Huub H van Rossum, Maarten J IJzerman, Michel M van den Heuvel, Hendrik Koffijberg
BACKGROUND: Patients treated with immune checkpoint inhibitors (ICI) are at risk of adverse events (AEs) even though not all patients will benefit. Serum tumor markers (STMs) are known to reflect tumor activity and might therefore be useful to predict response, guide treatment decisions and thereby prevent AEs. OBJECTIVE: This study aims to compare a range of prediction methods to predict non-response using multiple sequentially measured STMs. METHODS: Nine prediction models were compared to predict treatment non-response at 6-months (n = 412) using bi-weekly CYFRA, CEA, CA-125, NSE, and SCC measurements determined in the first 6-weeks of therapy...
August 2, 2023: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://read.qxmd.com/read/37393461/screening-approaches-for-lung-cancer-by-blood-based-biomarkers-challenges-and-opportunities
#4
REVIEW
Daniel van den Broek, Harry J M Groen
Lung cancer (LC) is one of the leading causes for cancer-related deaths in the world, accounting for 28% of all cancer deaths in Europe. Screening for lung cancer can enable earlier detection of LC and reduce lung cancer mortality as was demonstrated in several large image-based screening studies such as the NELSON and the NLST. Based on these studies, screening is recommended in the US and in the UK a targeted lung health check program was initiated. In Europe lung cancer screening (LCS) has not been implemented due to limited data on cost-effectiveness in the different health care systems and questions on for example the selection of high-risk individuals, adherence to screening, management of indeterminate nodules, and risk of overdiagnosis...
June 30, 2023: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://read.qxmd.com/read/37302060/pre-analytical-stability-of-the-cea-cyfra-21-1-nse-ca125-and-he4-tumor-markers
#5
JOURNAL ARTICLE
Esra Canki, Milou Mf Schuurbiers, Theodora C Linders, Catharina M Korse, Michel M van den Heuvel, Antonius E van Herwaarden, Huub H van Rossum
BACKGROUND: For lung cancer, circulating tumor markers (TM) are available to guide clinical treatment decisions. To ensure adequate accuracy, pre-analytical instabilities need to be known and addressed in the pre-analytical laboratory protocols. OBJECTIVE: This study investigates the pre-analytical stability of CA125, CEA, CYFRA 21.1, HE4 and NSE for the following pre-analytical variables and procedures; i) whole blood stability, ii) serum freeze-thaw cycles, iii) electric vibration mixing and iv) serum storage at different temperatures...
June 9, 2023: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://read.qxmd.com/read/37270828/circulating-tumor-dna-ctdna-as-a-biomarker-for-lung-cancer-early-detection-monitoring-and-therapy-prediction
#6
REVIEW
Michael J Duffy
Circulating tumor DNA (ctDNA), i.e., DNA shed from tumor cells into the bloodstream, is emerging as one of the most useful plasma biomarkers in patients with multiple types of cancer, including patients with non-small cell lung cancer (NSCLC). Indeed, NSCLC was the first malignancy in which measurement of ctDNA was approved for clinical use, i.e., mutational testing of EGFR for predicting response to EGFR tyrosine kinase inhibitors in patients with advanced disease. Although historically the gold standard method for EGFR mutational analysis required tumor tissue, the use of ctDNA is more convenient and safer for patients, results in a faster turn-around-time for return of results, provides a more complete representation of genetic alteration in heterogeneous tumors and is less costly to perform...
May 26, 2023: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://read.qxmd.com/read/37270827/blood-platelet-rna-profiles-do-not-enable-for-nivolumab-response-prediction-at-baseline-in-patients-with-non-small-cell-lung-cancer
#7
JOURNAL ARTICLE
Mirte Muller, Myron G Best, Vincent van der Noort, T Jeroen N Hiltermann, Anna-Larissa N Niemeijer, Edward Post, Nik Sol, Sjors G J G In 't Veld, Tineke Nogarede, Lisanne Visser, Robert D Schouten, Daan van den Broek, Karlijn Hummelink, Kim Monkhorst, Adrianus J de Langen, Ed Schuuring, Egbert F Smit, Harry J M Groen, Thomas Wurdinger, Michel M van den Heuvel
BACKGROUND: Anti-PD-(L)1 immunotherapy has emerged as a promising treatment approach for non-small cell lung cancer (NSCLC), though the response rates remain low. Pre-treatment response prediction may improve patient allocation for immunotherapy. Blood platelets act as active immune-like cells, thereby constraining T-cell activity, propagating cancer metastasis, and adjusting their spliced mRNA content. OBJECTIVE: We investigated whether platelet RNA profiles before start of nivolumab anti-PD1 immunotherapy may predict treatment responses...
May 26, 2023: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://read.qxmd.com/read/37248927/serum-tumor-markers-for-response-prediction-and-monitoring-of-advanced-lung-cancer-a-review-focusing-on-immunotherapy-and-targeted-therapies
#8
REVIEW
Michel van den Heuvel, Stefan Holdenrieder, Milou Schuurbiers, Daniel Cigoianu, Inga Trulson, Huub van Rossum, David Lang
BACKGROUND: The value of serum tumor markers (STMs) in the current therapeutic landscape of lung cancer is unclear. OBJECTIVE: This scoping review gathered evidence of the predictive, prognostic, and monitoring value of STMs for patients with advanced lung cancer receiving immunotherapy (IT) or targeted therapy (TT). METHODS: Literature searches were conducted (cut-off: May 2022) using PubMed and Cochrane CENTRAL databases. Medical professionals advised on the search strategies...
May 23, 2023: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://read.qxmd.com/read/36710691/clinical-perspectives-on-serum-tumor-marker-use-in-predicting-prognosis-and-treatment-response-in-advanced-non-small-cell-lung-cancer
#9
REVIEW
Alessandra I G Buma, Milou M F Schuurbiers, Huub H van Rossum, Michel M van den Heuvel
The optimal positioning and usage of serum tumor markers (STMs) in advanced non-small cell lung cancer (NSCLC) care is still unclear. This review aimed to provide an overview of the potential use and value of STMs in routine advanced NSCLC care for the prediction of prognosis and treatment response. Radiological imaging and clinical symptoms have shown not to capture a patient's entire disease status in daily clinical practice. Since STM measurements allow for a rapid, minimally invasive, and safe evaluation of the patient's tumor status in real time, STMs can be used as companion decision-making support tools before start and during treatment...
January 27, 2023: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://read.qxmd.com/read/37742670/induction-of-epithelial-mesenchymal-transition-in-thyroid-follicular-cells-is-associated-with-cell-adhesion-alterations-and-low-dose-hyper-radiosensitivity
#10
JOURNAL ARTICLE
Ankit Mathur, Vijayakumar Chinnadurai, Param Jit Singh Bhalla, Sudhir Chandna
BACKGROUND: Epithelial-mesenchymal transition (EMT) is associated with altered cellular adhesion. We previously demonstrated that cellular adhesion influences Low-dose Hyper-Radiosensitivity (HRS) in a variety of tumor cells. However, the relationship of low-dose HRS with the phenotypic plasticity incurred by EMT during the neoplastic transformation remains to be elucidated. OBJECTIVE: To investigate whether acquisition of EMT phenotype during progressive neoplastic transformation may affect low-dose radiation sensitivity...
2023: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://read.qxmd.com/read/37694332/suppression-of-kr%C3%A3-ppel-like-factor-5-basal-expression-by-creb1-binding-to-far-distal-element
#11
JOURNAL ARTICLE
Nozomi Mihara, Kazushi Imai
BACKGROUND: Krüppel-like factor 5 (KLF5) is a transcription factor regulating the proliferation and differentiation of epithelial cells, and its uncontrolled expression is closely associated with carcinoma progression. Sp3 binding to the minimal essential region (MER) of KLF5 gene is critical for KLF5 basal expression, but the expression control mechanism is unknown. OBJECTIVE: This study aimed to identify a regulatory region for KLF5 basal expression and the binding protein in carcinoma cells by analyzing the promoter upstream region...
2023: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://read.qxmd.com/read/37694331/small-interfering-rna-targeting-proprotein-convertase-subtilisin-kexin-type-9-might-promote-fatty-liver-disease-and-hepatocellular-carcinoma-through-upregulation-of-cd36
#12
JOURNAL ARTICLE
Frank S Fan
Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to low-density lipoprotein (LDL) receptor and fatty acid translocase CD36, inducing lysosomal degradation of these two receptors in the liver cells. Both monoclonal antibody (mAb) and small-interfering RNA (siRNA) targeting PCSK9 have been designed for treatment of familial hypercholesterolemia recently, with elevating LDL receptors on the liver cell surface and increasing LDL uptake as the main beneficial mechanism. However, given that the binding domains of PCSK9 for LDL receptor and CD36 are different, and PCSK9 mAb only attacks the domain for LDL receptor, CD36 expression remains partially controlled under PCSK9 mAb treatment...
2023: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://read.qxmd.com/read/37599553/retraction-to-microrna-25-suppresses-proliferation-migration-and-invasion-of-osteosarcoma-by-targeting-sox4
#13
(no author information available yet)
No abstract text is available yet for this article.
2023: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://read.qxmd.com/read/37599552/identification-of-hpv16-positive-cervical-cancer-subsets-characterized-by-divergent-immune-and-oncogenic-phenotypes-with-potential-implications-for-immunotherapy
#14
JOURNAL ARTICLE
Abhisikta Ghosh, Arnab Ghosh, Abarna Sinha, Sonia Mathai, Jaydip Bhaumik, Asima Mukhopadhyay, Arindam Maitra, Nidhan K Biswas, Partha P Majumder, Sharmila Sengupta
BACKGROUND: Cervical cancers (CaCx), like many other cancer types, portray high molecular heterogeneity that affects response to therapy, including immunotherapy. In India and other developing countries, CaCx mortality rates are very high because women report to the clinics with advanced cancers in absence of organized screening programs. This calls for implementation of newer therapeutic regimens for CaCx, like immunotherapy, which is again not used commonly in such countries. OBJECTIVE: Therefore, we focused on dissecting tumour immune heterogeneity, if any, identify immune gene-based biomarkers of heterogeneity and subsets of such cancers with the potential for immunotherapy...
2023: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://read.qxmd.com/read/37574746/co-expression-of-galectin-3-and-vimentin-in-triple-negative-breast-cancer-cells-promotes-tumor-progression-metastasis-and-survival
#15
JOURNAL ARTICLE
T Jeethy Ram, Asha Lekshmi, Pramod Darvin, Prakash Rajappan, K M Jagathnath Krishna, T M Anoop, Paul Augustine, Arun Peter Mathew, Kurian Cherian, Rexeena V Bhargavan, Thara Somanathan, M Radhakrishna Pillai, T R Santhosh Kumar, K Sujathan
BACKGROUND: Lack of druggable targets and complex expression heterogeneity of known targets is common among TNBC subtypes. An enhanced expression of galectin-3 in TNBCs has already been documented. We have observed a tumor progression-dependent galectin-3 expression in TNBCs compared to adjacent epithelium and non TNBCs. OBJECTIVE: To unravel the association of galectin- 3 in tumor progression, aggressiveness and drug resistance in TNBC patients. METHODS: Galectin-3 expression in 489 breast cancer tissues was correlated with clinicopathological features and the results were validated in cell lines and mouse model by silencing galectin-3 using shRNA and the proteins were profiled by western blot and qRT-PCR...
2023: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://read.qxmd.com/read/37393462/retraction-to-lncrna-gas5-inhibits-proliferation-and-progression-of-prostate-cancer-by-targeting-mir-103-through-akt-mtor-signaling-pathway
#16
(no author information available yet)
No abstract text is available yet for this article.
2023: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://read.qxmd.com/read/37212079/retraction-to-critical-role-for-the-long-non-coding-rna-afap1-as1-in-the-proliferation-and-metastasis-of-hepatocellular-carcinoma
#17
(no author information available yet)
No abstract text is available yet for this article.
2023: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://read.qxmd.com/read/37212078/retraction-to-mir-874-suppresses-the-proliferation-and-metastasis-of-osteosarcoma-by-targeting-e2f3
#18
(no author information available yet)
No abstract text is available yet for this article.
2023: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://read.qxmd.com/read/37125598/a-statement-regarding-the-mass-retraction-of-iranian-papers-in-november-2016
#19
JOURNAL ARTICLE
Aram Mokarizadeh
No abstract text is available yet for this article.
2023: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://read.qxmd.com/read/37038800/medium-and-large-alleles-of-the-pgc-gene-are-risk-factors-for-gastric-cancer
#20
JOURNAL ARTICLE
Josefina Yoaly Sánchez-López, Katia Carolina Vázquez-Ibarra, Andrea Marlene García-Muro, Azaria García-Ruvalcaba, Sergio Pacheco-Sotelo, Luis Carlos Díaz-Herrera, Marıa Eugenia Marin-Contreras
BACKGROUND: A 100-bp insertion/deletion polymorphism in the pepsinogen C gene has been associated with the risk of gastric cancer (GC). OBJECTIVE: We analyzed the relationships of the 100-bp insertion/deletion polymorphism with GC, atrophic gastritis (AG), and intestinal metaplasia (IM) in the Mexican general population (MGP). METHODS: We studied the genomic DNA of subjects with GC n = 80, AG and IM n = 60, controls n = 110, and the MGP n = 97...
2023: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
journal
journal
28852
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.